Position statement: Hypoglycemia management in patients with diabetes mellitus. Diabetes Mellitus Working Group of the Spanish Society of Endocrinology and Nutrition;Documento de posicionamiento: Evaluación y manejo de la hipoglucemia en el paciente concon diabetes mellitus. Grupo de Trabajo de Diabetes Mellitus de la Sociedad Española de Endocrinología y Nutrición

Endocrinologia y Nutricion

Volumn 60, Issue 9, 2013, Pages

  Mezquita Raya, Pedro ^a,b   Reyes García, Rebeca ^c   Moreno Pérez, Óscar ^d   Muñoz Torres, Manuel ^e   Merino Torres, Juan Francisco ^f   Gorgojo Martínez, Juan José ^g   Jódar Gimeno, Esteban ^h   Escalada San Martín, Javier ⁱ   Gargallo Fernández, Manuel ^j   Soto Gonzalez, Alfonso ^k   González Pérez de Villar, Noemí ^l   Becerra Fernández, Antonio ^m   Bellido Guerrero, Diego ⁿ   Botella Serrano, Marta ^o   Gómez Peralta, Fernando ^p   López de la Torre Casares, Martín ^q  

^a HOSPITAL TORRECÁRDENAS   (Spain)

^b Servicio de Endocrinología Clínica San Pedro   (Spain)

^c HOSPITAL GENERAL UNIVERSITARIO REINA SOFÍA   (Spain)

^d HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

^e HOSPITAL UNIVERSITARIO SAN CECILIO   (Spain)

^f HOSPITAL UNIVERSITARIO LA FE   (Spain)

^g HOSPITAL UNIVERSITARIO FUNDACIÓN ALCORCÓN   (Spain)

^h Hospital Universitario Quiron Madrid   (Spain)

ⁱ UNIVERSITY CLINIC OF NAVARRA   (Spain)

^j HOSPITAL UNIVERSITARIO INFANTA LEONOR   (Spain)

^k HOSPITAL JUAN CANALEJO   (Spain)

^l HOSPITAL UNIVERSITARIO DE FUENLABRADA   (Spain)

^m HOSPITAL RAMÓN Y CAJAL   (Spain)

ⁿ Universidad de La Coruña   (Spain)

^o HOSPITAL UNIVERSITARIO PRÍNCIPE DE ASTURIAS   (Spain)

^p HOSPITAL GENERAL DE SEGOVIA   (Spain)

^q HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES   (Spain)

more..

Author keywords

Consensus statement; Diabetes mellitus; Hipoglucemia; Hypoglycemia; Posicionamiento

Indexed keywords

ARTICLE; CLINICAL ASSESSMENT; DEVELOPMENT; DIABETES MELLITUS; DIABETIC PATIENT; EVALUATION; HUMAN; HYPOGLYCEMIA; MEDLINE; NUTRITION;

EID: 84887615343     PISSN: 15750922     EISSN: 15792021     Source Type: Journal    
DOI: 10.1016/j.endonu.2013.04.005     Document Type: Article

References (154)

1. Cryer P.E. Hypoglycaemia: The limiting factor in the glycaemic management of type I and type II diabetes. Diabetologia 2002, 45:937-948.
2. Position statement: Standards of medical care in diabetes-2013. Diabetes Care 2013, 36(Suppl 1):S11-S66. American Diabetes Association.
3. Bonds D.E., Miller M.E., Bergenstal R., Buse J.B., Byington R.P., Cutler J.A., et al. The association between severe symptomatic hypoglycaemia and mortality in type 2 diabetes: Retrospective analysis from the ACCORD Study. BMJ 2010, 340:4909-4918.
4. Patel A., MacMahon S., Chalmers J., Neal B., Billot L., Woodward M., et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008 12, 358:2560-2572. ADVANCE Collaborative Group.
5. Zoungas S., Patel A., Chalmers J., Galan B.E., Li Q., Billot L., et al. Severe hypoglycemia and risks of vascular events and death. N Engl J Med 2010, 363:1410-1418.
6. Brod M., Christensen T., Thomsen T.L., Bushnell D.M. The impact of non-severe hypoglycemic events on work productivity and diabetes management. Value Health 2011, 14:665-671.
7. Swiglo B.A., Murad M.H., Schunemann H.J., Kunz R., Vigersky R.A., Guyatt G.H., et al. A case for clarity, consistency, and helpfulness: State-of-the-art clinical practice guidelines in endocrinology using the grading of recommendations, assessment, development, and evaluation system. J Clin Endocrinol Metab 2008, 93:666-673.
8. Defining and reporting hypoglycemia in diabetes: a report from the American Diabetes Association Workgroup on Hypoglycemia. Diabetes Care 2005, 28:1245-1249. Workgroup on Hypoglycemia, American Diabetes Association.
9. Cryer P.E., Axelrod L., Grossman A.B., Heller S.R., Montori V.M., Seaquist E.R., et al. Evaluation and management of adult hypoglycemic disorders: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2009, 94:709-728.
10. Choudhary P., Amiel S.A. Hypoglycaemia: Current management and controversies. Postgrad Med J 2011, 87:298-306.
11. Frier B.M. Defining hypoglycaemia: What level has clinical relevance?. Diabetologia 2009, 52:31-34.
12. Swinnen S.G., Mullins P., Miller M., Hoekstra J.B., Holleman F. Changing the glucose cut-off values that define hypoglycaemia has a major effect on reported frequencies of hypoglycaemia. Diabetologia 2009, 52:38-41.
13. Cryer P.E., Davis S.N., Shamoon H. Hypoglycemia in diabetes. Diabetes Care 2003, 26:1902-1912.
14. Tesfaye N., Seaquist E.R. Neuroendocrine response to hypoglycemia. Ann N Y Acad Sci 2010, 1212:12-28.
15. Cryer P.E. Severe hypoglycemia predicts mortality in diabetes. Diabetes Care 2012, 35:1814-1816.
16. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin dependent diabetes mellitus. N Engl J Med 1993, 329:977-986. The Diabetes Control and Complications Trial Research Group.
17. Risk of hypoglycaemia in types 1 and 2 diabetes: Effects of treatment modalities and their duration. Diabetologia 2007, 50:1140-1147. UK Hypoglycaemia Study Group.
18. Reichard P., Pihl M. Mortality and treatment side-effects during long-term intensified conventional insulin treatment in the Stockholm Diabetes Intervention Study. Diabetes 1994, 43:313-317.
19. Lüddeke H.J., Sreenan S., Aczel S., Maxeiner S., Yeniqun M., Kozlovski P. PREDICTIVE-a global, prospective observational study to evaluate insulin detemir treatment in types 1 and 2 diabetes: Baseline characteristics and predictors of hypoglycemia from the European Cohort. Diabetes Obes Metab 2007, 9:428-434. on behalf of the PREDICTIVE Study Group.
20. Pickup J., Sutton A.J. Severe hypoglycaemia and glycemic control in type 1 diabetes: Meta-analysis of multiple daily insulin injections compared with continuous subcutaneous insulin infusion. Diabet Med 2008, 25:765-774.
21. Misso M.L., Egberts K.J., Page M., O'Connor D., Shaw J. Continuous subcutaneous insulin infusion (CSII) versus multiple insulin injections for type 1 diabetes mellitus. Cochrane Database Syst Rev 2010, 1:CD005103.
22. Bron M., Marynchenko M., Yang H., Yu A.P., Wu E.Q. Hypoglycemia, treatment discontinuation, and costs in patients with type 2 diabetes mellitus on oral antidiabetic drugs. Postgrad Med 2012, 124:124-132.
23. Leese G.P., Wang J., Broomhall J., Kelly P., Marsden A., Morrison W., et al. Frequency of severe hypoglycemia requiring emergency treatment in type 1 and type 2 diabetes: a population-based study of health service resource use. Diabetes Care 2003, 26:1176-1180.
24. Sarkar U. Hypoglycemia is more common among type 2 diabetes patients with limited health literacy: The Diabetes Study of Northern California (DISTANCE). J Gen Intern Med 2010, 25:962-968.
25. Bonds D.E., Miller M.E., Bergenstal R.M., Buse J.B., Byington R.P., Cutler J.A., et al. The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: Retrospective epidemiological analysis of the ACCORD study. BMJ 2010, 340:b4909.
26. Seaquist E.R., Miller M.E., Bonds D.E., Feinglos M., Goff D.C., Peterson K., et al. The impact of frequent and unrecognized hypoglycemia on mortality in the ACCORD study. Diabetes Care 2012, 35:409-414. ACCORD Investigators.
27. Zhao Y., Campbell C.R., Fonseca V., Shi L. Impact of hypoglycemia associated with antihyperglycemic medications on vascular risks in veterans with type 2 diabetes. Diabetes Care 2012, 35:1126-1132.
28. McCoy R.G., van Houten H.K., Ziegenfuss J.Y., Shah N.D., Wermers R.A., Smith S.A. Increased mortality of patients with diabetes reporting severe hypoglycemia. Diabetes Care 2012, 35:1897-1901.
29. Hsu P.F., Sung S.H., Cheng H.M., Yeh J.S., Liu W.L., Chan W.L., et al. Association of clinical symptomatic hypoglycemia with cardiovascular events and total mortality in type 2 diabetes mellitus: A nationwide population-based study. Diabetes Care 2013, 36:894-900.
30. Bloomfield HE, Greer N, Newman D, MacDonald R, Carlyle M, Fitzgerald P, et al. Predictors and consequences of severe hypoglycemia in adults with diabetes -A systematic review of the evidence. VA-ESP Project #09-009. 2012.
31. Johnston S.S., Conner C., Aagren M., Smith D.M., Bouchard J., Brett J. Evidence linking hypoglycemic events to an increased risk of acute cardiovascular events in patients with type 2 diabetes. Diabetes Care 2011, 34:1164-1170.
32. Gitt A.K., Bramlage P., Binz C., Krekler M., Plate T., Deeg E., et al. Hypoglycaemia is more frequent in type 2 diabetic patients with co-morbid vascular disease: An analysis of the DiaRegis registry. Eur J Prev Cardiol 2012, 19:765-772. DiaRegis Study Group.
33. Nathan D.M., Cleary P.A., Backlund J.Y., Genuth S.M., Lachin J.M., Orchard T.J., et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005, 353:2643-2653. Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group.
34. Giménez M., López J.J., Castell C., Conget I. Hypoglycaemia and cardiovascular disease in type 1 diabetes. Results from the Catalan National Public Health registry on insulin pump therapy. Diabetes Res Clin Pract 2012, 96:e23-e25.
35. Gruden G., Barutta F., Chaturvedi N., Schalkwijk C., Stehouwer C.D., Witte D.R., et al. Severe hypoglycemia and cardiovascular disease incidence in type 1 diabetes: The EURODIAB Prospective Complications Study. Diabetes Care 2012, 35:1598-1604.
36. Mayne D., Stout N.R., Aspray T.J. Diabetes, falls and fractures. Age Ageing 2010, 39:522-525.
37. Khazai N.B., Beck G.R., Umpierrez G.E. Diabetes and fractures: An overshadowed association. Curr Opin Endocrinol Diab Obes 2009, 16:435-445.
38. Johnston S.S., Conner C., Aagren M., Ruiz K., Bouchard J. Association between hypoglycaemic events and fall-related fractures in Medicare-covered patients with type 2 diabetes. Diabetes Obes Metab 2012, 14:634-643.
39. Monami M., Cresci B., Colombini A., Pala L., Balzi D., Gori F., et al. Bone fractures and hypoglycemic treatment in type 2 diabetic patients: A case-control study. Diabetes Care 2008, 31:199-203.
40. Kourtoglou G.I. Insulin therapy and exercise. Diabetes Res Clin Pract 2011, 93:S73-S77.
41. Rabasa-Lhoret R., Bourque J., Ducros F., Chiasson J.L. Guidelines for premeal insulin dose reduction for postprandial exercise of different intensities and durations in type 1 diabetic subjects treated intensively with a basal-bolus insulin regimen (ultralente-lispro). Diabetes Care 2001, 24:625-630.
42. Mauvais-Jarvis F., Sobngwi E., Porcher R., Garnier J.P., Vexiau P., Duvallet A., et al. Glucose response to intense aerobic exercise in type 1 diabetes: Maintenance of near euglycaemia despite a drastic decrease in insulin dose. Diabetes Care 2003, 26:1316-1317.
43. Physical activity/exercise and diabetes. Diabetes Care 2004, 27(suppl 1):S58-S62. American Diabetes Association.
44. Colberg S.R., Sigal R.J., Fernhall B., Regensteiner J.G., Blissmer B.J., Rubin R.R., et al. Exercise and type 2 diabetes: The American College of Sports Medicine and the American Diabetes Association: joint position statement executive summary. Diabetes Care 2010, 33:e147-e167.
45. Hernandez J.M., Moccia T., Fluckley J.D., Ulbrecht J.S., Farrell P.A. Fluid snacks to help persons with type 1 diabetes avoid late onset post-exercise hypoglycaemia. Med Sci Sports Exerc 2000, 32:904-910.
46. McMahon S.K., Ferreira L.D., Ratnam N., Davey R.J., Youngs L.M., Davis E.A., et al. Glucose requirements to maintain euglycaemia after moderate intensity afternoon exercise in adolescents with type 1 diabetes are increased in a biphasic manner. J Clin Endocrinol Metab 2007, 92:963-968.
47. MacDonald M.J. Postexercise late-onset hypoglycaemia in insulindependent diabetic patients. Diabetes Care 1997, 20:22-25.
48. Sandoval D.A., Aftab Guy D.L., Richardson M.A., Ertl A.C., Davis S.N. Effects of low and moderate antecedent exercise on counterregulatory responses to subsequent hypoglycaemia in type 1 diabetes. Diabetes 2004, 53:1798-1806.
49. Bussau V.A., Ferreira L.D., Jones T.W., Fournier P.A. A 10-s sprint performed prior to moderate-intensity exercise prevents early post-exercise fall in glycaemia in individuals with type 1 diabetes. Diabetologia 2007, 50:1815-1818.
50. Gallen I.W., Ballav C., Lumb A., Carr J. Caffeine supplementation reduces exercise induced decline in blood glucose and subsequent hypoglycaemia in adults with type 1 diabetes (T1DM) treated with multiple daily insulin injection (MDI). ADA 2010, Abstract 1184-P.
51. Gallen I.W., Hume C., Lumb A. Fuelling the athlete with type 1 diabetes. Diabetes Obes Metab 2011, 13:130-136.
52. Larsen J.J., Dela F., Madsbad S., Vibe-Petersen J., Galbo H. Interaction of sulfonylureas and exercise on glucose homeostasis in type 2 diabetic patients. Diabetes Care 1999, 22:1647-1654.
53. Galbo H., Tobin L., van Loon L.J. Responses to acute exercise in type 2 diabetes, with an emphasis on metabolism and interaction with oral hypoglycemic agents and food intake. Appl Physiol Nutr Metab 2007, 32:567-575.
54. Ajala O., English P., Pinkney J. Systematic review and meta-analysis of different dietary approaches to the management of type 2 diabetes. Am J Clin Nutr 2013, 97:505-516.
55. Franz M.J., Boucher J.L., Green-Pastors J., Powers M.A. Evidence-based nutrition practice guidelines for diabetes and scope and standards of practice. J Am Diet Assoc 2008, 108(Suppl 1):S52-S58.
56. Franz M.J., Bantle J.P., Beebe C.A., Brunzell J.D., Chiasson J.L., Garg A., et al. Evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes and related complications. Diabetes Care 2002, 25:148-198.
57. Wheeler M.L., Dunbar S.A., Jaacks L.M. Macronutrients, food groups, and eating patterns in the management of diabetes: A systematic review of the literature, 2010. Diabetes Care 2012, 35:434-445.
58. Buyken A.E., Toeller M., Heitkamp G., Karamanos B., Rottiers R., Muggeo M., et al. Glycemic index in the diet of European outpatients with type 1 diabetes: Relations to glycated hemoglobin and serum lipids. Am J Clin Nutr 2001, 73:574-581. EURODIAB IDDM Complications Study Group.
59. Thomas D., Elliott E.J. Low glycaemic index, or low glycaemic load, diets for diabetes mellitus. Cochrane Database Syst Rev 2009, 1:CD006296.
60. Nutrition recommendations and intervention for diabetes. A position statement of the American Diabetes Association. Diabetes Care 2008, 31(S1):S61-S78. American Diabetes Association.
61. Morris S., Wylie-Rosett J. Medical nutrition therapy: A key to diabetes management and prevention. Clinical Diabetes 2010, 26:12-18.
62. Dyson P.A., Kelly T., Deakin A., Duncan A., Frost G., Harrison Z., et al. Diabetes UK evidence-based nutrition guidelines for the prevention and management of diabetes. Diabet Med 2011, 28:1282-1288.
63. Howard A.A., Arnsten J.H., Gourevitch M.N. Effect of alcohol consumption on diabetes mellitus: A systematic review. Ann Inter Med 2004, 140:211-219.
64. Bennett W.L., Balfe L.M., Faysal J.M. AHRQ's Comparative effectiveness research on oral medications for type 2 diabetes: A summary of the key findings. J Manag Care Pharm 2012, 18(1-a):S3-S20.
65. Van de Laar F.A., Lucassen P.L., Akkermans R.P., van de Lisdonk E.H., Rutten G.E., van Weel C. Alpha-glucosidase inhibitors for patients with type 2 diabetes: Results from a Cochrane systematic review and meta-analysis. Diabetes Care 2005, 28:154-163.
66. Pan C., Yang W., Barona J.P., Wang Y., Niggli M., Mohideen P., et al. Comparison of vildagliptin and acarbose monotherapy in patients with Type 2 diabetes: A 24-week, double-blind, randomized trial. Diabet Med 2008, 25:435-441.
67. Ferrannini E., Ramos S.J., Salsali A., Tang W., List J.F. Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: A randomized, double-blind, placebo-controlled, phase 3 trial. Diabetes Care 2010, 33:2217-2224.
68. Henry R.R., Murray A.V., Marmolejo M.H., Hennicken D., Ptaszynska A., List J.F. Dapagliflozin, metformin XR, or both: initial pharmacotherapy for type 2 diabetes, a randomised controlled trial. Int J Clin Pract 2012, 66:446-456.
69. Zammitt N.N., Frier B.M. Hypoglycemia in type 2 diabetes: Pathophysiology, frequency, and effects of different treatment modalities. Diabetes Care 2005, 28:2948-2961.
70. Chu J., Stolbach A. Sulfonylurea agent poisoning. Uptodate. Literature review current through: Dec 2012 2012, Última actualización: 23 de julio.
71. Szoke E., Gosmanov N.R., Sinkin J.C., Nihalani A., Fender A.B., Cryer P.E., et al. Effects of glimepiride and glyburide on glucose counterregulation and recovery from hypoglycemia. Metabolism 2006, 55:78-83.
72. Bolen S., Feldman L., Vassy J., Wilson L., Yeh H.C., Marinopoulos S., et al. Systematic review: Comparative effectiveness and safety of oral medications for type 2 diabetes mellitus. Ann Intern Med 2007, 147:386-399.
73. Gangji A.S., Cukierman T., Gerstein H.C., Goldsmith C.H., Clase C.M. A systematic review and meta-analysis of hypoglycemia and cardiovascular events: a comparison of glyburide with other secretagogues and with insulin. Diabetes Care 2007, 30:389-394.
74. Phung O.J., Scholle J.M., Talwar M., Coleman C.I. Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetes. JAMA 2010, 303:1410-1418.
75. Liu S.C., Tu Y.K., Chien M.N., Chien K.L. Effect of antidiabetic agents added to metformin on glycaemic control, hypoglycaemia and weight change in patients with type 2 diabetes: a network meta-analysis. Diabetes Obes Metab 2012, 14:810-820.
76. Clar C., Gill J.A., Court R., Waugh N. Systematic review of SGLT2 receptor inhibitors in dual or triple therapy in type 2 diabetes. BMJ Open 2012, 2. pii: e001007.
77. Inzucchi S.E., Bergenstal R.M., Buse J.B., Diamant M., Ferrannini E., Nauck M., et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012, 35:1364-1379. American Diabetes Association (ADA); European Association for the Study of Diabetes (EASD).
78. Rossetti P., Pampanelli S., Fanelli C., Porcellati F., Costa E., Torlone E., et al. Intensive replacement of basal insulin in patients with type 1 diabetes given rapid-acting insulin analog at mealtime: A 3-month comparison between administration of NPH insulin four times daily and glargine insulin at dinner or bedtime. Diabetes Care 2003, 26:1490-1496.
79. De Leeuw I., Vague P., Selam J.L., Skeie S., Lang H., Draeger E., et al. Insulin detemir used in basal-bolus therapy in people with type 1 diabetes is associated with a lower risk of nocturnal hypoglycaemia and less weight gain over 12 months in comparison to NPH insulin. Diabetes Obes Metab 2005, 7:73-82.
80. Hermansen K., Davies M., Derezinski T., Martinez Ravn G., Clauson P., Home P. A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetes Care 2006, 29:1269-1274.
81. Riddle M.C. The Treat-to-Target Trial and related studies. Endocr Pract 2006, 12(Suppl 1):71-79.
82. CG87 Type 2 diabetes-newer agents (a partial update of CG66): short guideline. Disponible en: [consultado 15 Feb 2013]. http://www.nice.org.uk/guidance/index.jsp%3Faction=download%26o=44318.
83. DeWitt D.E., Hirsch I.B. Outpatient insulin therapy in type 1 and type 2 diabetes mellitus: scientific review. JAMA 2003, 289:2254-2264.
84. Siebenhofer A., Plank J., Berghold A., Jeitler K., Horvath K., Narath M., et al. Short acting insulin analogues versus regular human insulin in patients with diabetes mellitus. Cochrane Database Syst Rev 2006, CD003287.
85. Heller S.R., Colagiuri S., Vaaler S., Wolffenbuttel B.H., Koelendorf K., Friberg H.H., et al. Hypoglycaemia with insulin aspart: A double-blind, randomised, crossover trial in subjects with type1 diabetes. Diabet Med 2004, 21:769-775.
86. Plank J., Siebenhofer A., Berghold A., Jeitler K., Horvath K., Mrak P., et al. Systematic review and meta-analysis of short-acting insulin analogues in patients with diabetes mellitus. Arch Intern Med 2005, 165:1337-1344.
87. Zinman B., Tildesley H., Chiasson J.L., Tsui E., Strack T. Insulin lispro in CSII: Results of a double-blind crossover study. Diabetes 1997, 46:440-443.
88. Bode B., Weinstein R., Bell D., McGill J., Nadeau D., Raskin P., et al. Comparison of insulin aspart with buffered regular insulin and insulin lispro in continuous subcutaneous insulin infusion: A randomized study in type 1 diabetes. Diabetes Care 2002, 25:439-444.
89. Radermecker R.P., Scheen A.J. Continuous subcutaneous insulin infusion with short-acting insulin analogues or human regular insulin: Efficacy, safety, quality of life, and cost-effectiveness. Diabetes Metab Res Rev 2004, 20:178-188.
90. Siebenhofer A., Plank J., Berghold A., Horvath K., Sawicki P.T., Beck P., et al. Meta-analysis of short-acting insulin analogues in adult patients with type 1 diabetes: Continuous subcutaneous insulin infusion versus injection therapy. Diabetologia 2004, 47:1895-1905.
91. Ratner R.E., Gough S.C., Mathieu C., del Prato S., Bode B., Mersebach H., et al. Hypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes: A pre-planned meta-analysis of phase 3 trials. Diabetes Obes Metab 2013, 15:175-184.
92. Meier J.J. GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nat Rev Endocrinol 2012, 8:728-742.
93. Shyangdan D.S., Royle P., Clar C., Sharma P., Waugh N., Snaith A. Glucagon-like peptide analogues for type 2 diabetes mellitus. Cochrane Database Syst Rev 2011, CD006423.
94. Marre M., Shaw J., Brändle M., Bebakar W.M., Kamaruddin N.A., Strand J., et al. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU). Diabet Med 2009, 26:268-278. LEAD-1 SU study group.
95. Zinman B., Gerich J., Buse J.B., Lewin A., Schwartz S., Raskin P., et al. Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD). Diabetes Care 2009, 32:1224-1230. LEAD-4 Study Investigators.
96. Russell-Jones D., Vaag A., Schmitz O., Sethi B.K., Lalic N., Antic S., et al. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): A randomised controlled trial. Diabetologia 2009, 52:2046-2055. Liraglutide Effect and Action in Diabetes 5 (LEAD-5) met+SU Study Group.
97. Ridge T., Moretto T., Macconell L., Pencek R., Han J., Schulteis C., et al. Comparison of safety and tolerability with continuous (exenatide once weekly) or intermittent (exenatide twice daily) GLP-1 receptor agonism in patients with type 2 diabetes. Diabetes Obes Metab 2012, [Epub ahead of print]. 10.1111/j.1463-1326.2012.01639.x.
98. Buse J.B., Nauck M., Forst T., Sheu W.H., Shenouda S.K., Heilmann C.R., et al. Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): A randomised, open-label study. Lancet 2013, 381:117-124.
99. Seino Y., Min K.W., Niemoeller E., Takami A. Randomized, double-blind, placebo-controlled trial of the once-daily GLP-1 receptor agonist lixisenatide in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea (GetGoal-L-Asia). Diabetes Obes Metab 2012, 14:910-917. EFC10887 GETGOAL-L Asia Study Investigators.
100. Katz M.L., Volkening L.K., Anderson B.J., Laffel L.M. Contemporary rates of severe hypoglycaemia in youth with type 1 diabetes: Variability by insulin regimen. Diabet Med 2012, 29:926-932.
101. Miller M.E., Bonds D.E., Gerstein H.C., Seaquist E.R., Bergenstal R.M., Calles-Escandon J., et al. The effects of baseline characteristics, glycaemia treatment approach, and glycated haemoglobin concentration on the risk of severe hypoglycaemia: post hoc epidemiological analysis of the ACCORD study. BMJ 2010, 340:b5444.
102. Wagner V.M., Grabert M., Holl R.W. Severe hypoglycaemia, metabolic control and diabetes management in children with type 1 diabetes in the decade after the Diabetes Control and Complications Trial --a large-scale multicentre study. Eur J Pediatr 2005, 164:73-79.
103. Akram K., Pedersen-Bjergaard U., Carstensen B., Borch-Johnsen K., Thorsteinsson B. Frequency and risk factors of severe hypoglycaemia in insulin-treated Type 2 diabetes: a cross-sectional survey. Diabetic Med 2006, 23:750-756.
104. Quilliam B.J., Simeone J.C., Ozbay A.B. Risk Factors for hypoglycemia-related hospitalization in patients with type 2 diabetes: A Nested Case-Control Study. Clin Ther 2011, 33:1781-1791.
105. Rosenn B., Miodovnik M., Holcberg G. Hypoglycemia: The price of intensive insulin therapy for pregnant women with insulin-dependent diabetes mellitus. Obst Gyn 1995, 85:417-422.
106. Ringholm L., Pedersen-Bjergaard U., Thorsteinsson B., Damm P., Mathiesen E.R. Hypoglycaemia during pregnancy in women with type 1 diabetes. Diab Med 2012, 29:558-566.
107. Bhattacharyya A., Brown S., Hughes S., Vice P.A. Insulin lispro and regular insulin in pregnancy. QJM 2001, 94:255-260.
108. Mukhopadhyay A., Farrell T., Fraser R.B., Ola B. Continuous subcutaneous insulin infusion vs intensive conventional insulin therapy in pregnant diabetic women: a systematic review and metaanalysis of randomized, controlled trials. Am J Obs Gyn 2007, 197:447-456.
109. Lepercq J., Lin J., Hall G.C., Wang E., Dain M.P., Riddle M.C., et al. Meta-analysis of maternal and neonatal outcomes associated with the use of insulin glargine versus NPH insulin during pregnancy. Obstet Gynecol Int 2012, 2012:649070.
110. Mathiesen E.R., Hod M., Ivanisevic M., Duran Garcia S., Brøndsted L., Jovanovic L., et al. Maternal efficacy and safety outcomes in a randomized controlled trial comparing insulin detemir with NPH insulin in 310 pregnant women with type 1 diabetes mellitus. Diabetes Care 2012, 35:2012-2017.
111. Alagiakrishnan K., Mereu L. Approach to managing hypoglycemia in elderly patients with diabetes. Postgrad Med 2010, 122:129-137.
112. Avila-Fematt F.M., Montana-Alvarez M. Hypoglycemia in the elderly with diabetes mellitus. Rev Invest Clin 2010, 62:366-374.
113. Bree A.J., Puente E.C., Daphna-Iken D., Fisher S.J. Diabetes increases brain damage caused by severe hypoglycemia. Am J Physiol Endocrinol Metab 2009, 297:E194-E201.
114. Abbaszadeh Ahranjani S., Tabatabaei-Malazy O., Pajouhi M. Diabetes in old age, a review. J Diab Met Dis 2009, 8:113-128.
115. Chelliah A., Burge M.R. Hypoglycaemia in elderly patients with diabetes mellitus: Causes and strategies for prevention. Drugs Aging 2004, 21:511-530.
116. Barendse S., Singh H., Frier B.M., Speight J. The impact of hypoglycaemia on quality of life and related patient-reported outcomes in type 2 diabetes: A narrative review. Diab Med 2012, 29:293-302.
117. Duckworth W., Abraira C., Moritz T., Reda D., Emanuele N., Reaven P.D., et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009, 360:129-139.
118. Budnitz D.S., Lovegrove M.C., Shehab N., Richards C.L. Emergency hospitalizations for adverse drug events in older Americans. N Engl J Med 2011, 365:2002-2012.
119. Huelgas R.G., Díez-Espino J. Tratamiento de la diabetes tipo 2 en el paciente anciano. Med Clin (Barc) 2013, 140. 134.e1-134.e12.
120. Clinical practice guidelines for the prevention and management ofdDiabetes in Canada. CMAJ 2008, 32(Suppl 1). Canadian Diabetes Association.
121. Slama G., Traynard P.Y., Desplanque N., Pudar H., Dhunputh I., Letanoux M., et al. The search for an optimized treatment of hypoglycemia. Carbohydrates in tablets, solution, or gel for the correction of insulin reactions. Arch Intern Med 1990, 150:589-593.
122. Brodows R.G., Williams C., Amatruda J.M. Treatment of insulin reactions in diabetics. JAMA 1984, 252:3378-3381.
123. Aman J., Wranne L. Hypoglycaemia in childhood diabetes. II. Effect of subcutaneous or intramuscular injection of different doses of glucagon. Acta Paediatr Scand 1988, 77:548-553.
124. Patrick A.W., Collier A., Hepburn D.A., Steedman D.J., Clarke B.F., Robertson C. Comparison of intramuscular glucagon and intravenous dextrose in the treatment of hypoglycaemic coma in an accident and emergency department. Arch Emerg Med 1990, 7:73-77.
125. Collier A., Steedman D.J., Patrick A.W., Nimmo G.R., Matthews D.M., MacIntyre C.C., et al. Comparison of intravenous glucagon and dextrose in treatment of severe hypoglycemia in an accident and emergency department. Diabetes Care 1987, 10:712-715.
126. Saleh T.Y., Cryer P.E. Alanine and terbutaline in the prevention of nocturnal hypoglycemia in IDDM. Diabetes Care 1997, 20:1231-1236.
127. Watson J.M., Sherwin R.S., Deary I.J., Scott L., Kerr D. Dissociation of augmented physiological, hormonal and cognitive responses to hypoglycaemia with sustained caffeine use. Clin Sci (Lond) 2003, 104:447-454.
128. Gabriely I., Shamoon H. Fructose normalizes specific counterregulatory responses to hypoglycemia in patients with type 1 diabetes. Diabetes 2005, 54:609-616.
129. Hopkins D., Lawrence I., Mansell P., Thompson G., Amiel S., Campbell M., et al. Improved biomedical and psychological outcomes 1 year after structured education in flexible insulin therapy for people with type 1 diabetes the U.K. DAFNE experience. Diabetes Care 2012, 35:1638-1642.
130. Gimenez M., Lara M., Conget I. Sustained efficacy of continuous subcutaneous insulin infusion in type 1 diabetes subjects with recurrent non-severe and severe hypoglycemia and hypoglycemia unawareness: A pilot study. Diabetes Technol Ther 2010, 12:517-521.
131. Turnbull F.M., Abraira C., Anderson R.J., Byington R.P., Chalmers J.P., Duckworth W.C., et al. Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia 2009, 52:2288-2298.
132. Mannucci E., Monami M., Lamanna C., Gori F., Marchionni N. Prevention of cardiovascular disease through glycemic control in type 2 diabetes: A meta-analysis of randomized clinical trials. Nutr Metab Cardiovasc Dis 2009, 19:604-612.
133. Murata G.H., Hoffman R.M., Shah J.H., Wendel C.S., Duckworth W.C. A probabilistic model for predicting hypoglycemia in type 2 diabetes mellitus. The Diabetes Outcomes in Veterans Study (DOVES). Arch Intern Med 2004, 1643:1445-1450.
134. Monnier L., Wojtusciszyn A., Colette C., Owens D. The contribution of glucose variability to asymptomatic hypoglycemia in persons with type 2 diabetes. Diabetes Technol Ther 2011, 13:813-818.
135. Skyler J.S., Bergenstal R., Bonow R.O., Buse J., Deedwania P., Gale E.A.M., et al. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association. Diabetes Care 2009, 32:187-192.
136. Bergenstal R.M., Gavin J.R. The role of self-monitoring of blood glucose in the care of people with diabetes: report of a global consensus conference. Am J Med 2005, 118(Suppl 9A):1S-6S. Global Consensus Conference on Glucose Monitoring Panel.
137. Ziegler R., Heidtmann B., Hilgard D., Hofer S., Rosenbauer J., Holl R. Frequency of SMBG correlates with HbA1c and acute complications in children and adolescents with type 1 diabetes. Pediatr Diabetes 2011, 12:11-17. DPV- Wiss-Initiative.
138. Malanda U.L., Welschen L.M., Riphagen I.I., Dekker J.M., Nijpels G., Bot S.D. Self-monitoring of blood glucose in patients with type 2 diabetes mellitus who are not using insulin. Cochrane Database Syst Rev 2012, 18:CD005060.
139. Clar C., Barnard K., Cummins E., Royle P., Waugh N. Self-monitoring of blood glucose in type 2 diabetes: Systematic review. Health Technol Assess 2010, 14:1-140. Aberdeen Health Technology Assessment Group.
140. Sacks D.B., Arnold M., Bakris G.L., Bruns D.E., Horvath A.R., Kirkman M.S., et al. Position statement executive summary: guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus. Diabetes Care 2011, 34:1419-1423. National Academy of Clinical Bio- chemistry.
141. Tamborlane W.V., Beck R.W., Bode B.W., Buckingham B., Chase H.P., Clemons R., et al. Continuous glucose monitoring and intensive treatment of type 1 diabetes. N Engl J Med 2008, 359:1464-1476. Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group.
142. Beck R.W., Hirsch I.B., Laffel L., Tamborlane W.V., Bode B.W., Buckingham B., et al. The effect of continuous glucose monitoring in well-controlled type 1 diabetes. Diabetes Care 2009, 32:1378-1383. Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group.
143. Battelino T., Phillip M., Bratina N., Nimri R., Oskarsson P., Bolinder J. Effect of continuous glucose monitoring on hypoglycemia in type 1 diabetes. Diabetes Care 2011, 34:795-800.
144. Hoeks L.B., Greven W.L., de Valk H.W. Real-time continuous glucose monitoring system for treatment of diabetes: A systematic review. Diabet Med 2011, 28:386-394.
145. Langendam M., Luijf Y.M., Hooft L., Devries J.H., Mudde A.H., Scholten R.J. Continuous glucose monitoring systems for type 1 diabetes mellitus. Cochrane Database Syst Rev 2012, 1:CD008101.
146. Yeh H.C., Brown T.T., Maruthur N., Ranasinghe P., Berger Z., Suh Y.D., et al. Comparative effectiveness and safety of methods of insulin delivery and glucose monitoring for diabetes mellitus: A systematic review and meta-analysis. Ann Intern Med 2012, 157:336-347.
147. Golden S.H., Sapir T.J. Methods for insulin delivery and glucose monitoring in diabetes: Summary of a comparative effectiveness review. Manag Care Pharm 2012, 18(6 Suppl):S1-S17.
148. Golden SH, Brown T, Yeh HC, Maruthur N, Ranasinghe P, Berger Z, et al. Methods for insulin delivery and glucose monitoring: Comparative effectiveness. Rockville (MD): Agency for Healthcare Research and Quality (US); 2012 Jul. Report No.: 12-EHC036-EF. AHRQ Comparative Effectiveness Reviews.
149. Pickup J.C., Freeman S.C., Sutton A.J. Glycaemic control in type 1 diabetes during real time continuous glucose monitoring compared with self monitoring of blood glucose: Meta-analysis of randomised controlled trials using individual patient data. BMJ 2011, 343:d3805.
150. Floyd B., Chandra P., Hall S., Phillips C., Alema-Mensah E., Strayhorn G., et al. Comparative analysis of the efficacy of continuous glucose monitoring and self-monitoring of blood glucose in type 1 diabetes mellitus. J Diabetes Sci Technol 2012, 6:1094-1102.
151. Anderson J.E., Greene M.A., Griffin J.W., Kohrman D.B., Lorber D., Saudek C.D., et al. Diabetes and employment. Diabetes Care 2012, 1(Suppl):S94-S98. American Diabetes Association.
152. Ministerio de Fomento. ORDEN FOM/1267/2008, de 28 de abril, por la que se modifican la Orden de 21 de Mar de 2000, y la Orden FOM/2157/2003, de 18 de julio, que regulan diversos requisitos de las licencias de la tripulación de vuelo de aviones y helicópteros civiles, relativos a la organización médico-aeronáutica y la autorización de los centros médico-aeronáuticos y médicos examinadores. 2008.
153. Ministerio de la Presidencia. REAL DECRETO 772/1997, de 30 de May, por el que se aprueba el Reglamento General de Conductores. 1997.
154. Vicente-Herrero M.T., Sanchez-Juan M.J., Terradillo-García M.J., Aguilar-Jiménez E., Capdevilla-García L., Ramírez-Iñiguez de la Torre M.V., et al. Minusvalía e incapacidad en la diabetes y sus complicaciones. Una revisión de la legislación española. Av Diabetol 2010, 26:451-455.